Cargando…
The FDA-approved natural product dihydroergocristine reduces the production of the Alzheimer’s disease amyloid-β peptides
Known γ-secretase inhibitors or modulators display an undesirable pharmacokinetic profile and toxicity and have therefore not been successful in clinical trials for Alzheimer’s disease (AD). So far, no compounds from natural products have been identified as direct inhibitors of γ-secretase. To searc...
| Autores principales: | , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Nature Publishing Group
2015
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4644980/ https://www.ncbi.nlm.nih.gov/pubmed/26567970 http://dx.doi.org/10.1038/srep16541 |